Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 2/20 | 0.34 |
| ▸ | FLT3 | P36888 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | LMNA | P02545 | 3/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.32 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.32 |
| ▸ | PDCD1 | Q15116 | 4/20 | 0.32 |
| ▸ | CD274 | Q9NZQ7 | 4/20 | 0.32 |
| ▸ | HTR7 | P34969 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25975832 | 0.88 | PDCD1 (0.42) | JAK2FLT3LMNAADORA2AADORA1 | |
| SCHEMBL21626710 | 0.81 | LMNA (0.32) | ALDH1A1LMNAADORA2AADORA1 | |
| SCHEMBL17409808 | 0.81 | KMT2A (0.34) | ALDH1A1LMNATSHRMAPK1ADORA2A | |
| SCHEMBL21937114 | 0.81 | ABHD6 (0.42) | ADORA2ACYP2C19 | |
| SCHEMBL14907172 | 0.77 | CCR1 (0.34) | CYP2C19 | |
| SCHEMBL26032297 | 0.74 | — | — | |
| SCHEMBL14853093 | 0.71 | CYP2C19 (0.45) | ALDH1A1LMNATSHRADORA2AADORA1 | |
| SCHEMBL30073129 | 0.70 | LMNA (0.40) | ALDH1A1LMNATHRBTSHRMAPK1 | |
| SCHEMBL21622308 | 0.70 | DPP8 (0.41) | ALDH1A1LMNAADORA2APDCD1CD274 | |
| SCHEMBL14566143 | 0.70 | CDK4 (0.41) | JAK2LMNAADORA2AADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210147436-A1 | PYRROLIDINYL UREA DERIVATIVES AND APPLICATION THEREOF IN TRKA-RELATED DISEASES | ZHANGZHOU PIEN TZE HUANG PHARMACEUTICAL CO., LTD. (CN) | 2021-05-20 | — | — | US | disclosed |
| EP-3822266-A1 | PYRROLIDINYL UREA DERIVATIVES AND APPLICATION THEREOF IN TRKA-RELATED DISEASES | Zhangzhou Pien Tze Huang Pharmaceutical Co., Ltd (CN) | 2021-05-19 | — | — | EP | disclosed |
| WO-2020083377-A1 | PYRROLIDINYL UREA DERIVATIVES AND APPLICATION THEREOF | 南京明德新药研发有限公司 | 2020-04-30 | — | — | WO | disclosed |
| WO-2020011227-A1 | PYRROLIDINYL UREA DERIVATIVES AND APPLICATION THEREOF IN TRKA-RELATED DISEASES | 南京明德新药研发有限公司 | 2020-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210147436-A1 | PYRROLIDINYL UREA DERIVATIVES AND APPLICATION THEREOF IN TRKA-RELATED DISEASES | NGF, RET, NTRK1 | JAK2 1223/4885FLT3 81/4885ALDH1A1 2421/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.